抗瘤印 - 基衍生物的最新进展:一个迷你回顾
Guangyuan Liu1, Yawei Han1, Yuhao Wei1
1Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, No. 13 Hangkong Road, Wuhan 430030, China.
European journal of pharmacology
|December 21, 2025
概括
印度醇-酸盐衍生物通过准布林和DNA等关键分子,表现出强大的抗癌活性. 本综述探讨了它们的结构,点和在癌症治疗中的潜力,包括蛋白质溶解向奇美拉 (PROTAC) 技术.
科学领域:
- 药用化学 医学化学
- 有机化学 有机化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 石衍生物具有抗癌和抗炎性质,这是由于它们的α,β不和子结构.
- 印度尔基因是已知具有多种生物活性,包括抗癌作用的药理物.
- 结合英多尔和石支架提供了一种协同方法,以提高抗癌疗效.
研究的目的:
- 审查近期开发用于癌症治疗的印-基衍生物的进展.
- 检查这些化合物的各种结构框架和结构-活性关系.
- 分析它们的分子标,并探索蛋白质溶解向奇美拉 (PROTAC) 技术的应用.
主要方法:
- 关于印-基衍生物的最近研究的文献综述.
- 分析结构变化及其对生物活动的影响.
- 对分子标的研究,如图林,氨酸减少酶 (TrxR) 和碳酸无水酶IX (CA IX).
主要成果:
- 印度醇衍生物通过各种分子标表现出强大的抗癌作用.
- 特定的结构修改提高了它们对不同类型癌症的疗效.
- 蛋白质溶解向奇梅拉 (PROTAC) 技术在癌症治疗中对向蛋白质降解有望.
结论:
- 印度醇基衍生物代表了一类有前途的抗癌药物.
- 了解结构-活性关系和分子点对于优化它们的治疗潜力至关重要.
- 整合PROTAC技术可能会导致针对癌症治疗的新型向蛋白质降解策略.
更多相关视频
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
518
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
518
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
567
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
567
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
787
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
787
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


